Isolation of a novel basic FGF-binding peptide with potent antiangiogenetic activity

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Basic fibroblast growth factor (bFGF) is crucial for tumor angiogenesis and progression.
• bFGF signaling through its receptors represents a potential therapeutic target in cancer treatment.

Purpose of the Study:

• To identify and characterize novel bFGF antagonists.
• To evaluate the anti-angiogenic and anti-proliferative potential of a newly discovered peptide.

Main Methods:

• Screening of a phage display heptapeptide library against bFGF.
• Sequence analysis and homology comparison of identified peptides to bFGF receptors.
• Functional assays to assess inhibition of bFGF-induced cell proliferation and neovascularization.

Main Results:

• Eleven specific bFGF-binding phage clones were identified.
• A peptide, P7, showed homology to the Ig-like domain III of FGFR1 and FGFR2.
• Synthetic P7 peptides potently inhibited bFGF-induced cell proliferation and neovascularization.

Conclusions:

• The P7 peptide acts as a potent bFGF antagonist.
• P7 exhibits significant anti-angiogenetic activity.
• P7 holds therapeutic potential for cancer treatment by targeting angiogenesis.